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BACKGROUND: This study examined the risk of third cancer of non-breast origin (TNBC) among women with bilateral breast cancer
(BBC; either synchronous or metachronous), focussing on the relation with breast cancer treatment.
METHODS: Risk was assessed, among 8752 Dutch women diagnosed with BBC between 1989 and 2008, using standardised incidence
ratios (SIR) and Cox regression analyses to estimate the hazard ratio (HR) of TNBC for different treatment modalities.
RESULTS: Significant increased SIRs were observed for all TNBCs combined, haematological malignancies, stomach, colorectal, non-
melanoma skin, lung, head and neck, endometrial, and ovarian cancer. A 10-fold increased risk was found for ovarian cancer among
women younger than 50 years (SIR¼ 10.0, 95% confidence interval (CI)¼ 5.3–17.4). Radiotherapy was associated with increased
risks of all TNBCs combined (HR¼ 1.3; 95%CI¼ 1.1–1.6, respectively). Endocrine therapy was associated with increased risks of all
TNBCs combined (HR¼ 1.2; 95%CI¼ 1.0–1.5), haematological malignancies (HR¼ 2.0; 95%CI¼ 1.1–3.9), and head and neck cancer
(HR¼ 3.3; 95%CI¼ 1.1–10.4). After chemotherapy decreased risks were found for all TNBCs combined (HR¼ 0.63;
95%CI¼ 0.5–0.87).
CONCLUSION: Increased risk of TNBC could be influenced by genetic factors (ovarian cancer) or an effect of treatment (radiotherapy
and endocrine therapy). More insight in the TNBC risk should further optimise and individualise treatment and surveillance protocols
in (young) women with BBC.
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Breast cancer is by far the most frequent cancer in European and
North American women (Parkin et al, 2005). Owing to earlier
diagnosis and improved treatment, breast cancer survival has
increased, increasing the risk of metachronous breast cancer,
among the survivors (Sant et al, 2001). Women with a history of
breast cancer have a 2–3-fold higher risk of developing a
contralateral breast cancer as compared to the general female
population (Soerjomataram et al, 2005; Levi et al, 2006;
Mellemkjaer et al, 2006; Schaapveld et al, 2008). In a Dutch
population-based study, 18% of breast cancer patients were
diagnosed with a second breast cancer in the period 1989–2006
(Liu et al, 2011). Similar results were observed among women at
high risk, who either had a unilateral breast cancer or a twin sister
with breast cancer; 9–18% experienced a breast cancer event after
20 years of follow-up (Hartman et al, 2008). However, incidence
declined since 1980 due to the increasing use of adjuvant therapy
(Hartman et al, 2007).
Besides an elevated risk of contralateral breast cancer, several
studies revealed that women with a primary breast cancer have an
increased risk of developing a subsequent non-breast cancer.
Increased risks were most consistently found for tumours of the
ovary, endometrium, soft tissue and for leukaemia (Rubino et al,
2000; Evans et al, 2001; Soerjomataram et al, 2005; Levi et al, 2006;
Mellemkjaer et al, 2006; Prochazka et al, 2006; Kirova et al, 2008;
Schaapveld et al, 2008; Cortesi et al, 2009; Berrington de et al,
2010). Excess risks of melanoma of the skin and cancer of the
bone, oesophagus, kidney and lung have also been reported,
though less consistently (Rubino et al, 2000; Evans et al, 2001;
Soerjomataram et al, 2005; Mellemkjaer et al, 2006; Prochazka
et al, 2006; Schaapveld et al, 2008; Cortesi et al, 2009; Berrington de
et al, 2010). Risks of subsequent non-breast cancer appears to be
associated with genetic and other risk factors that are common for
both, breast cancer patients with primary breast cancer experi-
enced an increased risk of lung cancer and soft tissue sarcomas
that could be attributed to radiation. Increased risks of melanoma
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of the skin, uterine cancer and leukaemia were found to be
associated with the use of chemotherapy for patients older than 50
years, whereas the increased risk of endometrial cancer was related
to endocrine therapy. At the same time, chemotherapy was
associated with a reduced risk of colon and lung cancer for
women younger than 50 years (Schaapveld et al, 2008).
However, information about the risk of third cancer of non-breast
origin (third non-breast cancer; TNBC) after synchronous or
metachronous invasive bilateral breast cancer (BBC) is lacking.
Patients with BBC may have been exposed to more carcinogenic or
carcino-protective cancer treatment. Moreover, a higher risk could
be expected for genetic, reproductive or lifestyle-related cancers.
More insight in these risks may further optimise and individualise
surveillance protocols in women with BBC. Therefore, we assessed in
this study the risks of TNBC after BBC in a nationwide study based
on the Netherlands Cancer Registry (NCR). In addition, we studied
the associations of TNBC risk with breast cancer treatment.
MATERIALS AND METHODS
The cohort: BBC patients
Patients were selected from the population-based nationwide
NCR that reached complete coverage of cancer incidence in the
Netherlands since 1989 (Comprehensive Cancer Centre Netherland
(IKNL), 2011). Patient registration is based on notification on a
weekly basis of all newly diagnosed malignancies by the automated
national pathology archive and a yearly link with the national
registry of hospital discharge diagnoses. In case of multiple
primaries, the definition of a new primary tumour is a primary
cancer that is not an extension, a recurrence or a metastasis of a
known tumour, located at another anatomic site or when arising in
the same anatomic site, belonging to a different histological
subgroup or to a different behaviour subgroup (in situ vs invasive
growth). Subsequently, information on patient and tumour
characteristics and primary treatment are retrieved directly from
the medical records by specially trained registrars. Staging is coded
according to the tumour, node and metastasis system (TNM)
classification (Wittekind et al, 2004); topography and histology are
coded according to the International Classification of Diseases for
Oncology (ICD-O; Fritz et al, 2000). Basic treatment information
was available: whether patients were surgical treated, received
radiotherapy, chemotherapy or endocrine therapy. Data on vital
status and migration are annually updated through linkage with
the national population demographics registry of the municipal
administrations (Gemeentelijke basisadministratie). Data quality is
high (Schouten et al, 1993b), and data completeness is estimated to
be at least 95% (Schouten et al, 1993a).
All women diagnosed with BBC, defined as invasive first breast
cancer and a synchronous or metachronous invasive second
contralateral primary breast cancer (without cancer before the first
breast cancer or between the first and second breast cancer), between
1989 and 2008 in the Netherlands were selected (n¼ 9718). Bilateral
breast cancer patients were excluded with a metastasis at time of
diagnosis of the first or second breast cancer (stage IV, n¼ 909), with
a sarcoma of the breast either for the first or second breast cancer
(morphology code 8830–9990, n¼ 17), as well as patients who
developed a third primary breast cancer after BBC (n¼ 40). In total,
8752 women with BBC were included in our study.
Statistical analysis
The patient and tumour characteristics are reported as frequencies
and compared using w2 test. To estimate the risks of TNBC after
BBC standardised incidence ratios (SIR) were calculated. The SIR
is the ratio of the observed to the expected numbers of TNBC
cases. Observed numbers are the TNBC cases diagnosed during
follow-up period. Patients with zero follow-up time between
second breast cancer and the TNBC or the end of study period
were excluded for the SIR calculation (n¼ 6). To determine the
expected numbers, person years at risk by 5-year age categories
and 1-year calendar period categories were multiplied with the
corresponding background cancer incidence in the general Dutch
female population and then summed up. Person years at risk
started at the second breast cancer diagnosis and ended at the date
of TNBC diagnosis, date of death or the end of the study period
(e.g., 31 December 2008), whichever came first. A SIR value higher
than 1 implies an increased risk, whereas values lower than 1
suggest a decreased risk. Ninety-five per cent confidence intervals
(95%CI) were estimated assuming Poisson distribution of the
TNBC occurrence. Standardised incidence ratios were computed
for three age categories based on age at time of the second breast
cancer diagnosis (o50, 50–64 and 65þ years) and for four follow-
up intervals since the second breast cancer diagnosis (o1, 1–5,
6–10 and 410 years), and were plotted on a log scale. These
subgroup analysis makes comparison with other studies possible
and could give additional information in order to discuss and
explain other outcomes. Tests for linear trend in relation to period
of diagnosis were performed by incorporating a parameter in the
relevant Poisson regression model with consecutive non-negative
integer values corresponding to increasing or decreasing levels of
the factor and comparing the deviance statistic with that of a
model without the relevant parameter.
Multivariable Cox proportional hazard analysis was used to
examine the effect of breast cancer treatment on the different
TNBC risks. The follow-up time was defined as the time between
the date of first breast cancer diagnosis and the date of TNBC
diagnosis. Patients were censored at the date of death, migration or
the end of the study period (e.g., 31 December 2008). Proportional
hazards were tested for all entered variables using graphical
(Kaplan–Meier plots) and statistical methods. The interval between
first and second breast cancer (BCFI) appeared to be a non-
proportional factor and therefore analyses were stratified by BCFI
categories (o1, 1–5, 6–10 and 410 years) using the strata option
in STATA. Factors included in the model were treatment of first
breast cancer (radiotherapy (no, yes), chemotherapy (no, yes),
endocrine therapy (no, yes)), age at first breast cancer (o50, 50–64
and 65þ ), year of first breast cancer incidence (continue variable).
Second breast cancer treatment variables (radiotherapy (no, yes),
chemotherapy (no, yes), endocrine therapy (no, yes)) were entered
to the model as time-dependent covariates, allocating patients to
no second breast cancer treatment until second breast cancer
occurrence.
Statistical significance was defined as a two-sided P-value of less
than 0.05. Statistical analyses were performed in SAS version 9.2
(SAS Institute, Cary, NC, USA).
RESULTS
In the Netherlands, eligible 8752 patients were diagnosed with
invasive BBC between 1989 and 2008, with a median time of 2.4
years between the first and second breast cancer (Table 1). The
patients accumulated 44 399 person years of follow-up since
second breast cancer. Overall, 586 patients developed TNBC with
a median follow-up time between the second breast cancer and
TNBC of 3.9 years. Compared with patients without TNBC,
patients with TNBC were significantly (Po0.001) more likely to
be older than 65 years at first and second breast cancer diagnosis
(respectively, 40% vs 47% and 59% vs 49%), had more often a stage
I second breast cancer (61% vs 53%), were more often surgical
treated for first and second breast cancer (respectively, 98% vs 95%
and 96% vs 92%) and received less often chemotherapy for
first and second breast cancer (respectively, 9% vs 19% and
9% vs 19%).
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Risk of TNBC compared with the general female
population
Table 2 shows the observed and expected numbers of TNBC and
SIRs for TNBC by cancer site. The risk of all TNBCs combined
after BBC was 1.6 (95%CI¼ 1.5–1.7). Elevated risks were seen for
head and neck, stomach, lung, soft tissue, non-melanoma skin,
ovarian, endometrial, other female genital organs and kidney
cancer, and haematological malignancies.
The risk of TNBCs overall was highest among women younger
than 50 years at diagnosis of second breast cancer (SIR¼ 2.8,
95%CI¼ 2.1–3.5; Figure 1). Differences between age groups were
especially large for ovarian cancer, with a relative risk of 10
(95%CI¼ 5.3–17.4) in women younger than 50 years at second
breast cancer diagnosis. Relative risks for endometrial, stomach
and kidney cancer were highest for patients older than 65 years
(respective SIR¼ 3.4; 95%CI¼ 2.3–4.5, SIR¼ 2.3; 95%CI¼ 1.4–3.6
and SIR¼ 2.9; 95%CI¼ 1.6–4.9). Overall, the risk of TNBCs tended
Table 1 Patient and tumour characteristics of patients with bilateral breast cancer
Total With TNBC Without TNBC
N (%) N (%) N (%) Pa
Total 8752 586 8166
Age at first breast cancer o0.001
o50 years 2245 (26) 106 (18) 2139 (26)
50–64 years 2993 (34) 206 (35) 2787 (34)
65þ years 3514 (40) 274 (47) 3240 (40)
Age at second breast cancer o0.001
o50 years 1470 (17) 65 (11) 1405 (17)
50–64 years 2922 (33) 175 (30) 2747 (34)
65þ years 4360 (50) 346 (59) 4014 (49)
Time between first and second breast cancer 0.552
Median (25–75% range) 2.4 (0.04–6.1) 2.2 (0.03–5.6) 2.4 (0.04–6.2)
o1 year 3243 (37) 225 (38) 3018 (37)
41–5 years 2687 (31) 186 (32) 2501 (31)
45–10 years 1882 (22) 121 (21) 1761(22)
410 years 940 (11) 54 (9) 886 (11)
Time between second breast cancer and TNBC
Median (25–75% range) NA 3.9 (1.5–7.2) NA
o1 year NA 102 (17) NA
41–5 years NA 255 (44) NA
45–10 years NA 166 (28) NA
410 years NA 63 (11) NA
Stage of first breast cancer 0.024
I 3712 (42) 249 (43) 3463 (42)
II 3402 (39) 253 (43) 3149 (39)
III 682 (8) 34 (6) 648 (8)
Unknown 956 (11) 50 (9) 906 (11)
Stage of second breast cancer o0.001
I 4664 (53) 359 (61) 4305 (53)
II 2832 (32) 170 (29) 2662 (33)
III 618 (7) 25 (4) 593 (7)
Unknown 638 (7) 32 (5) 606 (7)
Treatment
Surgery
First breast cancer 8303 (95) 573 (98) 7730 (95) 0.001
Second breast cancer 8063 (92) 565 (96) 7498 (92) o0.001
Radiotherapy
First breast cancer 4698 (54) 325 (55) 4373 (54) 0.371
Second breast cancer 3620 (41) 249 (42) 3371 (41) 0.565
Chemotherapy
First breast cancer 1640 (19) 50 (9) 1590 (19) o0.001
Second breast cancer 1628 (19) 55 (9) 1573 (19) o0.001
Endocrine therapy
First breast cancer 2638 (30) 171 (29) 2467 (30) 0.600
Second breast cancer 3417 (39) 209 (36) 3208 (39) 0.083
Abbreviations: NA¼ not applicable; TNBC¼ third non-breast cancer. Bold entries denote statistical significance. aP value w2 test indicating differences between patients with and
without TNBC.
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to slightly increase with longer follow-up time since second breast
cancer diagnosis (Figure 2). Increasing SIRs over time were seen
for lung and ovarian cancer and haematological malignancies. For
kidney and head and neck cancer, the SIRs tended to decrease with
time. No significant trends with follow-up time were found.
Risk of TNBC compared within the cohort
Table 3 shows the independent effects of cancer treatment on the
risk of developing TNBC. Except for lung, ovarian and head and
neck cancer, the risk of TNBC was highest in the older age patients.
For lung, ovarian and head and neck cancer, a decreased risk was
seen for patients older than 65 years of age (respective hazard ratio
(HR)¼ 0.47; 95%CI¼ 0.23–0.95, HR¼ 0.13; 95%CI¼ 0.03–0.49
and HR¼ 0.07; 95%CI¼ 0.11–0.39). Chemotherapy for the first
breast cancer was associated with a decreased risk of all TNBCs
combined (HR¼ 0.63; 95%CI¼ 0.45–0.87). After radiotherapy for
the second breast cancer, increased risks were found for all TNBCs
combined (HR¼ 1.3; 95%CI¼ 1.1–1.6). After endocrine therapy
for the second breast cancer, risks increased for all TNBCs
combined (HR¼ 1.2; 95%CI¼ 1.0–1.5), haematological (HR¼ 2.0;
95%CI¼ 1.1–3.9) and head and neck cancer (HR¼ 3.3;
95%CI¼ 1.1–10.4).
DISCUSSION
This is the first population-based study reporting the risks for
TNBC in patients with BBC. Results showed an elevated risk for all
TNBCs combined, and a more than two-fold increased risk of head
and neck, stomach, lung, soft tissue, ovarian, endometrial, other
female genital organs and kidney cancer was found for women
with BBC compared with women without cancer. The risk was
highest for women with BBC younger than 50 years at time of their
Table 2 Observed and expected numbers and SIRs with 95%
confidence intervals for third non-breast cancers after bilateral breast
cancer
Site of TNBC
Observed
numbers
Expected
numbers SIR 95%CI
Head and neck 18 9 2.0 1.2–3.2
Thyroid 3 2 1.4 0.29–4.6
Oesophagus 5 6 0.84 0.27–2.1
Stomach 25 12 2.1 1.4–3.2
Pancreas 15 12 1.2 0.67–2.0
Liver, intrahepatic
bile ducts and biliary
tract
7 5 1.5 0.60–3.2
Colorectal 91 74 1.2 0.99–1.5
Digestive organs,
other
5 3 1.6 0.52–3.9
Lung 77 35 2.2 1.7–2.8
Soft tissue 8 2 3.6 1.5–7.3
Melanoma of skin 25 18 1.4 0.89–2.1
Non-melanoma skin 80 50 1.6 1.3–2.0
Ovarian 33 14 2.3 1.6–3.4
Endometrial 58 22 2.6 2.0–3.4
Cervix uteri 5 5 0.97 0.31–2.4
Vulva 5 4 1.1 0.36–2.8
Female
genitalorgans, othera
6 1 4.6 1.7–10.4
Urinary bladder 19 15 1.3 0.78–2.0
Kidney 20 8 2.4 1.5–3.8
Brain 2 4 0.50 0.06–2.1
Haematological 48 33 1.5 1.1–1.9
All TNBCsb 582 363 1.6 1.5–1.7
Abbreviations: CI¼ confidence interval; SIR¼ standardised incidence ratio; TNBC¼
third non-breast cancer. Bold entries denote statistical significance. aIncluded, not
otherwise specified and vagina. bIncluded others than the specific sites denoted: renal
pelvis (2 observed cases), thymus (1 observed case), eye (3 observed cases), other or
unspecified sites (4 observed cases), primary sites unknown (10 observed cases) and
benign brain tumour (7 observed cases).
P = 0.093 P = 0.913 P = 0.564 P = 0.401 P = 0.161 P = 0.269 P < 0.001 P = 0.484 P = 0.713 P = 0.009
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Figure 1 SIRs, 95%CI and P values for trend analyses for selected third non-breast cancers (410 cases, increased SIR overall) according to the age at
second breast cancer diagnosis. *Non-mel. skin¼ non-melanoma skin.
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second breast cancer. Especially marked was the 10-fold increased
risk of ovarian cancer among young BBC patients. Interestingly,
chemotherapy was associated with a reduced risk of all TNBCs
combined.
Studies among patients with primary breast cancer reported a
23–40% increased risk of subsequent cancer (Rubino et al, 2000;
Mellemkjaer et al, 2006; Cortesi et al, 2009). Our results showed an
elevated risk of all TNBCs combined after BBC (SIR¼ 1.6;
95%CI¼ 1.5–1.7), and even higher risks (SIR¼ 2.8) were found
in women younger than 50 years at second breast diagnosis. Other
studies support higher risks for subsequent breast cancer after
primary breast cancer in young women with SIRs varying from 1.3
to 5.5 (Soerjomataram et al, 2005; Mellemkjaer et al, 2006;
Prochazka et al, 2006; Yu et al, 2006; Andersson et al, 2008). The
high risk of TNBC in young women overall is influenced by the
marked 10-fold increased risk of ovarian cancer among women
younger than 50 years (SIR¼ 10). This is likely related to BRCA
mutations. Women with BRCA1 or BRCA2 are prone to early age
breast cancer, multiple breast cancers and have a higher risk of
developing an ovarian cancer (Welcsh and King, 2001).
Radiotherapy is widely used for treatment of breast cancer. Over
time modern radiation techniques reduce the exposure of normal
tissue around the breast. Increased risks after radiation exposure
of subsequent cancers of the oesophagus, lung, thyroid gland, soft
tissue and leukaemia have been earlier reported (Rubino et al,
2000; Zablotska and Neugut, 2003; Roychoudhuri et al, 2004; Levi
et al, 2006; Andersson et al, 2008; Kirova et al, 2008; Schaapveld
et al, 2008; Berrington de et al, 2010). Our study showed excess
risk of all TNBC after BBC for patients treated with radiotherapy
for the second breast cancer. Although increased risk of lung
cancer was expected among women with previous radiotherapy
(Zablotska and Neugut, 2003; Roychoudhuri et al, 2004; Berrington
de et al, 2010), we observed no significant relation between
radiation and lung cancer. We found elevated risks for lung cancer
after a longer follow-up period (SIR¼ 3.1 after 5 years of follow-up).
From literature it is known that there is at least a 5-year lag period
between radiation exposure and cancer induction (PHASE 2
Committee to Assess Health Risks from Exposure to Low Levels of
Ionising Radiation, 2006). Furthermore, Kaufman et al (2008) found
no elevated risks for lung cancer among non-smoking breast cancer
patients after radiotherapy. However, among ever-smokers without
radiotherapy and ever-smokers treated with radiotherapy, the risk of
lung cancer was significantly increased (odds ratio (OR)¼ 5.9 and
OR¼ 18.9, respectively). Unfortunately, no information about
smoking was available in this study, hence it remains important to
study the effect of radiotherapy on lung cancer taking smoking in to
account.
Owing to their radiosensitivity, even ovaries, though further
located from the breast, are prone to biological changes related to
radiation (Rubin and Casarett, 1968). Two large studies found a
relation between radiation of the breast and higher risk of
subsequent ovarian cancer (Kirova et al, 2008; Berrington de
et al, 2010). Although other studies found no relation (Rubino
et al, 2000; Andersson et al, 2008) or even an adverse effect for
women older than 50 years treated with radiotherapy (Schaapveld
et al, 2008), we found a non-significant increased risk of ovarian
cancer after radiotherapy for the second breast cancer.
Our results showed a decreased risk after chemotherapy for the
first breast cancer for all TNBCs combined, and it may have a
protective effect for colorectal, lung, ovarian and head and neck
cancer. In addition, younger BBC patients had a higher risk of
lung, ovarian and head and neck cancer than those older than 65
years of age. Schaapveld et al (2008) showed a protective effect of
chemotherapy only among women younger than 50 years for all
second non-breast cancers combined, colon and lung cancer. The
study of Andersson et al (2008) found in univariable analyses a
protective effect of chemotherapy for bladder cancer. Rubino et al
(2000) found no risk differences of TNBC after primary breast
cancer treated with or without chemotherapy; however, informa-
tion on chemotherapy was lacking in this study. An explanation
P = 0.413 P = 0.147 P = 0.260 P = 0.108 P = 0.100 P = 0.110 P = 0.870 P = 0.214 P = 0.806 P = 0.932
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Figure 2 SIRs, 95%CI and P values for trend analyses for selected third non-breast cancers (410 cases, increased SIR overall) according to follow-up time
since second breast cancer diagnosis. *Non-mel. skin¼ non-melanoma skin.
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for the protective effect might be that TNBCs undergo a growth
delay from the use of chemotherapy. Especially for colon cancer
fluorouracil-containing chemotherapy could be effective.
Acute myeloid leukaemia is considered as a (anthracycline-
containing) chemotherapy-induced cancer, which can present
within a few years after breast cancer diagnosis (Valagussa et al,
1994; Diamandidou et al, 1996; Chaplain et al, 2000). We observed
no association between chemotherapy and increased risks for
haematological malignancies, probably because this group not
only contains acute myeloid leukaemia but also (non) Hodgkin’s
lymphoma and other types of leukaemia. Surprisingly, we found a
significant higher risk of haematological malignancies for patients
treated with endocrine therapy. As far as we know, this association
was not earlier reported and we could not find a clear explanation
for this association.
Since 1975 tamoxifen is used for the treatment of postmeno-
pausal breast cancer in patients with positive oestrogen receptor.
Tamoxifen is linked to a 1.3–7.5-fold increased risk of endometrial
cancer (van Leeuwen et al, 1994; Bergman et al, 2000; Polin and
Ascher, 2008). Although no significant relation was found between
endocrine treatment and the risk of endometrial cancer within the
group of BBC patients, we found a two-fold elevated risk for
endometrial cancer after BBC compared with the general female
population, particularly for women older than 65 years at second
breast cancer diagnosis and women treated with endocrine therapy
(results not shown). However, in line with other studies, the SIR
for endometrial cancer was also increased for women who received
no endocrine therapy (results not shown; Schaapveld et al, 2008).
Therefore, other shared risk factors like family history, reproduc-
tive factors (e.g., parity, hormone replacement treatment) or high
body mass index probably contribute to the increased risk of
endometrial cancer (Grady et al, 1995; Bernstein, 2002; Reeves
et al, 2007; Reeves et al, 2012).
Some strengths and limitations of our study should be
considered. The strengths of this study include the large
population-based cohort with nearly complete follow-up data for
vital status and TNBC that enables us to provide reliable estimates
of TNBC risk after BBC and effects of treatment. However,
information of other risk factors such as lifestyle factors, including
smoking, alcohol consumption and body mass index, as well as
genetic factors were not available.
Treatment information was restricted. No information was
available about the specific type of radiotherapy and the doses. We
found no significant differences in TNBC risks between patients
treated with radiation for the first or the second breast cancer. As
we included BBC patients, radiotherapy was given on different
sites of the body so a cumulative effect could be expected for ovary
and endometrial cancer and leukaemia, because of the equal
distant to both sites and the radiosensitivity. Furthermore,
information of specific endocrine therapy was not available in
our database. Apart from tamoxifen, aromatase inhibitors or
luteinising hormone-releasing hormone agonists have been
administered. Therefore, the effect of endocrine therapy could be
slightly underestimated.
Risks were estimated for the first and second breast cancer
treatment. Patients with synchronous breast cancer could have
received chemotherapy or endocrine therapy for both breasts;
however, in fact they received only one dosage. Although the Cox
regression model was corrected for BCFI and variables for second
breast cancer treatment were incorporated as time-dependent
covariates, outcomes need to be interpreted with caution.
CONCLUSION
Women with BBC had a 1.5 times higher risk of all TNBCs
combined. Young women had a 2.8 times higher risk of all TNBCs
combined and a 10-fold higher risk of ovarian cancer, compared
with the general population, which is probably related to genetic
factors. Chemotherapy was associated with a decreased risk of all
TNBCs combined, whereas radiotherapy and endocrine therapy
were associated with a increased risk. Next to the relations between
treatment and the risk of TNBC and the possible role of genetics,
shared environmental factors are likely to be involved for most
elevated risks. Therefore, follow-up care should also be focussed
on improving healthy lifestyle. This study gave more insight in the
risks of TNBC and results could further optimise and individualise
treatment and surveillance protocols in (young) women with BBC.
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Table 3 Multivariate Cox regression analyses for the association of risk of selected third non-BC (410 cases, increased SIR overall) with BC treatment
All TNBCs Stomach Colorectal Lung
Non-melanoma
skin Endometrial Ovarian Kidney Haematological Head and neck
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
No. of patients 583 25 91 77 80 58 33 20 49 18
Age at first BC diagnosis (years)
o50 1 1 1 1 1 1 1 1 1 1
50–64 1.3 (1.0–1.7) 2.5 (0.45–13.5) 3.5 (1.3–9.2) 1.0 (0.58–1.8) 1.9 (0.82–4.2) 2.1 (0.82–5.1) 0.63 (0.29–1.4) 1.2 (0.32–4.8) 1.6 (0.66–3.9) 0.45 (0.14–1.4)
65þ 1.8 (1.4–2.3) 8.1 (1.5–43.8) 6.4 (2.4–17.1) 0.47 (0.23–0.95) 4.6 (2.0–10.6) 3.2 (1.2–8.3) 0.13 (0.03–0.49) 1.9 (0.46–8.1) 2.2 (0.87–5.6) 0.07 (0.11–0.39)
Incidence year first
BC
1.1 (1.0–1.1) 1.0 (0.91–1.1) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.1 (1.1–1.2) 1.0 (0.93–1.1) 0.93 (0.84–1.0) 1.0 (0.88–1.1) 1.1 (1.01–1.2) 1.0 (0.91–1.2)
First BC
Radiotherapy 1.1 (0.87–1.3) 1.8 (0.71–5.0) 0.69 (0.42–1.2) 0.93 (0.56–1.6) 1.5 (0.88–2.5) 0.69 (0.37–1.3) 1.4 (0.60–3.1) 1.6 (0.58–4.3) 1.6 (0.82–3.1) 2.9 (0.87–9.9)
Chemotherapy 0.63 (0.45–0.87) 0.32 (0.03–3.2) 0.40 (0.11–1.5) 0.49 (0.21–1.2) 1.4 (0.61–3.3) 1.1 (0.41–3.2) 0.24 (0.05–1.1) 0.28 (0.03–2.4) 0.82 (0.29–2.3) 0.13 (0.01–1.2)
Endocrine
therapy
1.0 (0.82–1.3) 1.2 (0.43–3.5) 0.63 (0.34–1.2) 1.2 (0.66–2.3) 0.69 (0.37–1.3) 1.4 (0.70–2.7) 1.2 (0.38–3.5) 1.7 (0.60–5.0) 0.62 (0.27–1.4) 2.0 (0.54–7.3)
Second BC
Radiotherapy 1.3 (1.1–1.6) 1.6 (0.63–4.2) 1.4 (0.8–2.4) 1.5 (0.89–2.5) 1.1 (0.68–1.9) 1.3 (0.69–2.4) 1.8 (0.82–4.0) 0.90 (0.33–2.5) 1.1 (0.56–2.1) 0.74 (0.26–2.1)
Chemotherapy 0.93 (0.67–1.3) 2.3 (0.38–14.0) 0.80 (0.25–2.6) 0.58 (0.25–1.4) 0.55 (0.19–1.6) 0.95 (0.31–2.9) 0.95 (0.33–2.7) 2.1 (0.48–8.8) 0.70 (0.22–2.2) 0.54 (0.10–2.8)
Endocrine
therapy
1.2 (1.0–1.5) 0.66 (0.22–2.0) 1.5 (0.87–2.5) 1.08 (0.61–1.9) 1.6 (0.94–2.7) 1.5 (0.81–2.9) 0.57 (0.20–1.7) 2.3 (0.86–6.1) 2.0 (1.1–3.9) 3.3 (1.1–10.4)
Abbreviations: BC¼ breast cancer; CI¼ confidence interval; HR¼ hazard ratio; SIR¼ standardised incidence ratio; TNBC¼ third non-breast cancer. Bold entries denote
statistical significance.
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